Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1824
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
MK-1824 is an investigational, long-acting natriuretic peptide receptor-A (NPR-A) agonist developed by Merck & Co. (known as MSD outside the U.S. and Canada). It is primarily being evaluated for the treatment of heart failure with preserved ejection fraction (HFpEF). NPR-A is a transmembrane receptor that, upon activation by natriuretic peptides like atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), catalyzes the production of cyclic guanosine monophosphate (cGMP). This signaling pathway mediates vasodilation, natriuresis, and diuresis, and exerts anti-fibrotic and anti-hypertrophic effects on the myocardium. MK-1824 is designed to provide sustained activation of this pathway to improve hemodynamics and cardiac remodeling in heart failure patients. It is currently in Phase 1 clinical development.
Beyond the preview
Go deeper on MK-1824.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1824.